Rosiglitazone revisited: an updated meta-analysis of risk for myocardial infarction and cardiovascular mortality.
暂无分享,去创建一个
[1] S. Nissen. The rise and fall of rosiglitazone. , 2010, European heart journal.
[2] C. Deangelis,et al. Ensuring integrity in industry-sponsored research: primum non nocere, revisited. , 2010, JAMA.
[3] S. Nissen. Setting the RECORD Straight. , 2010, JAMA.
[4] Diane M. Miller,et al. Effect of Rosiglitazone on Progression of Coronary Atherosclerosis in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease: The Assessment on the Prevention of Progression by Rosiglitazone on Atherosclerosis in Diabetes Patients With Cardiovascular History Trial , 2010, Circulation.
[5] S. Schinner. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial , 2010 .
[6] R. Prentice,et al. Variation in event rates in trials of patients with type 2 diabetes. , 2009, JAMA.
[7] M. Hanefeld,et al. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial , 2009, The Lancet.
[8] D. Nathan. Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy: A Consensus Statement of the American Diabetes Association and the European Association for the Study of Diabetes , 2009, Diabetes Care.
[9] B. Zinman,et al. Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy , 2009, Diabetes Care.
[10] G. Koch,et al. A retrospective evaluation of congestive heart failure and myocardial ischemia events in 14 237 patients with type 2 diabetes mellitus enrolled in 42 short‐term, double‐blind, randomized clinical studies with rosiglitazone , 2008, Pharmacoepidemiology and drug safety.
[11] Gergana G. Nestorova,et al. Transcriptome Alteration in the Diabetic Heart by Rosiglitazone: Implications for Cardiovascular Mortality , 2008, PloS one.
[12] J. Leahy. Uncertain Effects of Rosiglitazone on the Risk for Myocardial Infarction and Cardiovascular Death , 2008 .
[13] L. Kennedy. Rosiglitazone Evaluated for Cardiovascular Outcomes—An Interim Analysis , 2008 .
[14] Yoon K Loke,et al. Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis. , 2007, JAMA.
[15] C. Rosen. The rosiglitazone story--lessons from an FDA Advisory Committee meeting. , 2007, The New England journal of medicine.
[16] M. Hanefeld,et al. Rosiglitazone evaluated for cardiovascular outcomes--an interim analysis. , 2007, The New England journal of medicine.
[17] S. Nissen,et al. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. , 2007, The New England journal of medicine.
[18] Jonathan J Deeks,et al. Much ado about nothing: a comparison of the performance of meta‐analytical methods with rare events , 2007, Statistics in medicine.
[19] B. Zinman,et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. , 2006, The New England journal of medicine.
[20] M. Laakso,et al. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial , 2006, The Lancet.
[21] Erland Erdmann,et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial , 2005, The Lancet.
[22] Alfonso T. Perez,et al. A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia. , 2005, Diabetes care.
[23] Shankar Subramaniam,et al. Variance-modeled posterior inference of microarray data: detecting gene-expression changes in 3T3-L1 adipocytes , 2004, Bioinform..
[24] G. Harris. Glaxo agrees to post results of drug trials on web site. , 2004, The New York times on the Web.
[25] Alexander J Sutton,et al. What to add to nothing? Use and avoidance of continuity corrections in meta-analysis of sparse data. , 2004, Statistics in medicine.
[26] L. V. Van Gaal,et al. Addition of rosiglitazone to metformin is most effective in obese, insulin‐resistant patients with type 2 diabetes , 2003, Diabetes, obesity & metabolism.
[27] Nicola J Cooper,et al. Meta-analysis of rare and adverse event data , 2002, Expert review of pharmacoeconomics & outcomes research.
[28] G. Grunberger,et al. Once- and twice-daily dosing with rosiglitazone improves glycemic control in patients with type 2 diabetes. , 2001, Diabetes care.
[29] M. Stewart,et al. Thiazolidinediones for type 2 diabetes. All glitazones may exacerbate heart failure. , 2001, BMJ.
[30] H. Lebovitz,et al. The Journal of Clinical Endocrinology & Metabolism Printed in U.S.A. Copyright © 2001 by The Endocrine Society Rosiglitazone Monotherapy Is Effective in Patients with Type 2 Diabetes , 1999 .
[31] J. Rosenstock,et al. Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus: a randomized controlled trial. , 2000, JAMA.
[32] W. Haenszel,et al. Statistical aspects of the analysis of data from retrospective studies of disease. , 1959, Journal of the National Cancer Institute.